t71vt2

Property	Value
?:abstract	INTRODUCTION: Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. Previous studies reported pulmonary embolism (PE) in severe COVID-19 patients. Aim of the study was to estimate the prevalence of symptomatic PE in COVID-19 patients and to identify the clinical, radiological or biological characteristics associated with PE. PATIENTS/METHODS: We conducted a retrospective nested case-control study in 2 French hospitals. Controls were matched in a 1:2 ratio on the basis of age, sex and center. PE patients with COVID-19 were compared to patients in whom PE was ruled out (CTPA controls) and in whom PE has not been investigated (CT controls). RESULTS: PE was suspected in 269 patients among 1042 COVID-19 patients, and confirmed in 59 patients (5.6%). Half of PE was diagnosed at COVID-19 diagnosis. PE patients did not differ from CT and CTPA controls for thrombosis risk factors. PE patients more often required invasive ventilation compared to CTPA controls (odds ratio (OR) 2.79; 95% confidence interval (CI) 1.33–5.84) and to CT controls (OR 8.07; 95% CI 2.70–23.82). PE patients exhibited more extensive parenchymal lesions (>50%) than CT controls (OR 3.90; 95% CI 1.54–9.94). D-dimer levels were 5.1 (95% CI 1.90–13.76) times higher in PE patients than CTPA controls. CONCLUSIONS: Our results suggest a PE prevalence in COVID-19 patients close to 5% in the whole population and to 20% of the clinically suspected population. PE seems to be associated with more extensive lung damage and to require more frequently invasive ventilation.
is ?:annotates of	<https://research.tib.eu/covid-19/entity/79t71vt2_hasAnnotation_C0034065> <https://research.tib.eu/covid-19/entity/79t71vt2_hasAnnotation_C0037090> <https://research.tib.eu/covid-19/entity/79t71vt2_hasAnnotation_C0040053> <https://research.tib.eu/covid-19/entity/79t71vt2_hasAnnotation_C0161816>
?:creator	<https://research.tib.eu/covid-19/entity/Planquette%2C_Benjamin%3B_Le_Berre%2C_Alice%3B_Khider%2C_Lina%3B_Yannoutsos%2C_Alexandra%3B_Gendron%2C_Nicolas%3B_de_Torcy%2C_Marie%3B_Mohamedi%2C_Nassim%3B_Jouveshomme%2C_St%C3%A9phane%3B_Smadja%2C_David_M.%3B_Lazareth%2C_Isabelle%3B_Goudot%2C_Guillaume%3B_Fournier%2C_Laure%3B_Bruel%2C_C%C3%A9dric%3B_Diehl%2C_Jean_Luc%3B_Mourad%2C_Jean-Jacques%3B_Meyer%2C_Guy%3B_Priollet%2C_Pascal%3B_Messas%2C_Emmanuel%3B_Sanchez%2C_Olivier%3B_Beaussier%2C_H%C3%A9l%C3%A8ne%3B_Mirault%2C_Tristan%3B_Zins%2C_Marc%3B_Chatelier%2C_Gilles%3B_Emmerich%2C_Joseph>
?:doi	10.1016/j.thromres.2020.11.001
?:doi	<https://research.tib.eu/covid-19/entity/10.1016/j.thromres.2020.11.001>
?:journal	Thromb_Res
?:license	no-cc
?:pdf_json_files	document_parses/pdf_json/3baccaea333603509c96781255b3ba480c060ed1.json
?:pmc_json_files	document_parses/pmc_json/PMC7648521.xml.json
?:pmcid	<https://research.tib.eu/covid-19/entity/PMC7648521>
?:pmid	<https://research.tib.eu/covid-19/entity/33190025.0>
?:pmid	33190025.0
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/79t71vt2_HAS_C0005779_COEXISTS_WITH_C5203670> <https://research.tib.eu/covid-19/entity/79t71vt2_HAS_C0161816_COEXISTS_WITH_C5203670> <https://research.tib.eu/covid-19/entity/79t71vt2_HAS_C0651007_PREDISPOSES_C0040053> <https://research.tib.eu/covid-19/entity/79t71vt2_HAS_C2744535_ASSOCIATED_WITH_C0034065>
?:sha_id	<https://research.tib.eu/covid-19/entity/3baccaea333603509c96781255b3ba480c060ed1>
?:source	Elsevier; Medline; PMC
?:title	Prevalence and characteristics of pulmonary embolism in 1042 COVID-19 patients with respiratory symptoms: A nested case-control study
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:year	2020-11-07

Property

Value

?:abstract

INTRODUCTION: Coronavirus disease 2019 (COVID-19) has been associated with cardiovascular complications and coagulation disorders. Previous studies reported pulmonary embolism (PE) in severe COVID-19 patients. Aim of the study was to estimate the prevalence of symptomatic PE in COVID-19 patients and to identify the clinical, radiological or biological characteristics associated with PE. PATIENTS/METHODS: We conducted a retrospective nested case-control study in 2 French hospitals. Controls were matched in a 1:2 ratio on the basis of age, sex and center. PE patients with COVID-19 were compared to patients in whom PE was ruled out (CTPA controls) and in whom PE has not been investigated (CT controls). RESULTS: PE was suspected in 269 patients among 1042 COVID-19 patients, and confirmed in 59 patients (5.6%). Half of PE was diagnosed at COVID-19 diagnosis. PE patients did not differ from CT and CTPA controls for thrombosis risk factors. PE patients more often required invasive ventilation compared to CTPA controls (odds ratio (OR) 2.79; 95% confidence interval (CI) 1.33–5.84) and to CT controls (OR 8.07; 95% CI 2.70–23.82). PE patients exhibited more extensive parenchymal lesions (>50%) than CT controls (OR 3.90; 95% CI 1.54–9.94). D-dimer levels were 5.1 (95% CI 1.90–13.76) times higher in PE patients than CTPA controls. CONCLUSIONS: Our results suggest a PE prevalence in COVID-19 patients close to 5% in the whole population and to 20% of the clinically suspected population. PE seems to be associated with more extensive lung damage and to require more frequently invasive ventilation.

is ?:annotates of